← Back to headlines
FDA to Review Savara's Resubmitted Molbreevi BLA
The FDA is set to review Savara's resubmitted Biologics License Application (BLA) for Molbreevi, indicating a new phase in the drug's regulatory process.
20 Feb, 21:42 — 20 Feb, 21:42
ℹOnly 1 source covers this story
